|The following article is part of conference coverage from the 17th St. Gallen International Breast Cancer Symposium, which is being held virtually from March 7-21, 2021. The team at Cancer Therapy Advisor will be reporting on the latest research conducted by leading experts in breast cancer. Check back for more from the 17th St. Gallen International Breast Cancer Symposium.|
Locoregional treatment was found to improve survival for patients with de novo stage IV breast cancer and bone-only metastasis, according to the results of a multicenter registry study reported at the 17th St. Gallen International Breast Cancer Conference 2021.
BOMET MF14-01 (ClinicalTrials.gov Identifier: NCT02125630) included 505 patients with de novo stage IV breast cancer and bone-only metastasis. Patients were grouped by treatment type: 240 patients who received systemic treatment and 265 patients who received locoregional treatment.
Within the locoregional treatment group, patients were further categorized by timing of surgery: 180 patients who received systemic treatment after locoregional treatment and 85 patients who received systemic treatment before locoregional treatment.
At a median follow-up of 34 months, a higher proportion of patients in the systemic treatment group died compared with the locoregional treatment group (35.4% vs 10.5%). The rate of local progression was also higher in patients receiving systemic treatment group compared with those receiving locoregional treatment (16.2% vs 6.7%; P =.001).
Patients in the locoregional treatment group had a 60% reduced likelihood of dying compared with patients in the systemic treatment group (hazard ratio=0.40; 95% CI, 0.30-0.54, P <.0001).
This survival benefit was seen for both subgroups in the locoregional treatment group (both P <.0001) compared with the systemic treatment group, suggesting that the timing of locoregional treatment does not influence survival.
The study authors concluded that locoregional treatment prolonged survival and decreased locoregional recurrence at the median 3-year follow-up.
“For current practice while planning treatment of patients with only bone metastases at the time of diagnosis, the primary LRT [locoregional treatment] alternative can be discussed in tumor board and with patient.”
Visit Cancer Therapy Advisor’s conference section for more coverage of the 17th St. Gallen International Breast Cancer Symposium.
Soran A, Dogan L, Ozbas S, et al; Breast Health Working Group International on behalf of Turkish Federation of Breast Disease Societies. The effect of primary surgery in patients with stage IV breast cancer with bone metastasis only (protocol BOMET MF14-01); a multi-center, registry study. Poster presentation at: The 17th St. Gallen International Breast Cancer Conference 2021; March 17-21, 2021. Abstract P126.